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Abstract
Background: The purpose of this study was to assess the efficacy of Bacillus Calmette-Guerin (BCG) therapy after a
second transurethral resection (TUR) in new onset high-grade T1 bladder cancer.
Methods: From January 2008 to September 2013, 207 patients with new onset high-grade T1 bladder cancer after
an initial TUR were treated at our university and at affiliated hospitals. Residual cancer rate, intravesical recurrence-
free survival (RFS), and risk factors for intravesical recurrence were analyzed.
Results: Among a total of 207 patients, 42 patients were treated with BCG therapy following a second TUR (group 1),
23 were treated with second TUR alone (group 2), 72 were treated with BCG alone (group 3), and 70 were treated
without a second TUR or BCG. The median patients’ age was 72.0 years, and the median follow-up period
was 33.5 months. The second TUR revealed that 34 patients (52 %) had residual cancer. Between groups 1
and 2 and groups 1 and 3, the differences in RFS were statistically significant (p = 0.002 and 0.045, respectively). In
addition, BCG therapy was the most significant factor to predict RFS after the second TUR. Among the 31 patients
whose pathology of the second TUR was pT0, only 1 of 12 patients (8 %) in group 1 and 11 of 19 patients (58 %) in
group 2 had a recurrence.
Conclusions: BCG instillation following a second TUR decreases intravesical recurrence, even if the pathology of the
second TUR is pT0.
Keywords: BCG induction instillation, Intravesical recurrence, New onset, Second transurethral resection of bladder
tumor, Urothelial carcinoma high grade
Background
Among the non-muscle-invasive bladder cancers
(NMIBCs), high-grade T1 bladder cancer presents high
risk of intravesical recurrence after an initial transurethral
resection (TUR). Bacillus Calmette-Guerin (BCG) induc-
tion instillation after an initial TUR is effective, reducing
the risk of recurrence and progression [1–6]. A second
TUR, which is defined as a repeated TUR performed
within 2–8 weeks following an initial TUR, has been
recommended since the 2000s for both resecting re-
sidual tumor and detecting staging error [1–6]. Accord-
ing to clinical guidelines, BCG induction instillations
after a second TUR are recommended especially in
cases with residual tumors in the second TUR [7]. A
second TUR reduces the number of residual tumors
and enhances the effects of intravesical BCG therapy;
however, we are lacking large cohorts on the efficacy of
BCG therapy when the pathology of the second TUR is
pT0.
In this study, we performed an analysis of 207 patients
with new onset high-grade T1 bladder cancer and
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evaluated the efficacy of BCG induction instillations
following a second TUR.
Methods
Between April 2008 and September 2013, 327 patients
were diagnosed with high-grade T1 bladder cancer at
the initial TUR at Nagoya City University Hospital and
at five affiliated hospitals. We excluded patients who
underwent intravesical chemotherapy after an initial
TUR or a second TUR, recurrent cases and patients with
clinical muscle-invasive bladder cancer. The clinical
course of the 327 patients diagnosed with high-grade T1
bladder cancer is listed in Fig. 1. We also excluded
patients with more than 12-week intervals between the
initial TUR and the second TUR. Excluding these
patients, we retrospectively analyzed 207 patients. Written
informed consent was acquired from all participants.
Among consecutive 207 patients, 114 patients received
BCG induction instillation (Tokyo 172 strain, purchased
from Nihon BCG, Tokyo, Japan) within 2–4 weeks fol-
lowing an initial TUR or a second TUR. Patients youn-
ger than 80 years received 80 mg BCG, and patients
older than 80 years received 40 mg BCG per instillation
(eight times once a week). Some patients terminated
BCG induction instillation because of side effects, but a
minimum of four applications was performed in all of
them. Patients didn’t receive maintenance BCG therapy.
All patients underwent a second TUR with deep
muscle fibers in the resected specimen on an initial
TUR. In the second TUR, we resected the scar of the
initial TUR deeply enough in the muscle fiber and also
resected 1 cm around the tumor margin. The initial
TUR and the second TUR were performed either by be-
ginners with the instruction of experienced urologists or
Fig. 1 Clinical course of 327 patients diagnosed with high-grade T1 bladder cancer. Group 1: BCG induction instillations after the second TUR,
group 2: second TUR alone, group 3: BCG induction instillations alone, group 4: neither a second TUR nor BCG induction instillations. BCG: Bacillus
Calmette-Guerin; TUR: transurethral resection
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by experienced urologists themselves. Tumor specimens
were classified according to the Union for International
Cancer Control–TNM classification 6th edition and the
World Health Organization 2004 classification.
During the weekly BCG treatment, a follow-up was
performed monitoring patients’ temperature change,
bladder irritation, and other symptoms. After termin-
ation of the treatment, urine cytology and cystoscopy
were performed every 3 months during the first 3 years
and every 4–12 months thereafter. We performed en-
hanced computed tomography in common practice dur-
ing follow-up, but there was not unified intergroup
imaging protocol for the patients with normal urine cy-
tology and no recurrence on cystoscopy. We defined the
day of the intravesical recurrence as the day when blad-
der cancer was pathologically identified.
The end point of this study was the intravesical recur-
rence. Differences in categorical parameters were
assessed using t-test, Kruskal–Wallis test, and Fisher’s
exact test. The recurrence-free survival (RFS) curves
were estimated by the Kaplan–Meier method, and log-
rank test was applied to compare survival between
groups. To identify risk factors for the intravesical recur-
rence after the second TUR, we evaluated seven variables
(age, gender, urine cytology before the initial TUR, tumor
size, tumor number, concomitant carcinoma in situ [CIS]
and BCG induction instillation after the initial TUR) by
univariate and multivariate analysis using the Cox propor-
tional hazard regression model. A P-value < 0.05 was con-
sidered to indicate a statistically significant difference.
Statistical analyses were performed using the EZR soft-
ware (Saitama Medical Center, Jichi Medical University,
Yakushiji, Japan). This study was approved by our institu-
tional research ethics committee (Nagoya City University
ethical board No. 1153).
Results
The median age was 72.0 years (range: from 39 to
93 years). The patients were followed up until March
2014 and the median follow-up period was 33.5 months
(range: from 2.9 to 69.5 months). Patients’ characteristics
are shown in Table 1. Of the 207 patients who were di-
agnosed with high-grade T1 bladder cancer, 65 received
a second TUR (31 %) and 142 (69 %) did not (Table 1).
BCG induction instillations after the second TUR were
performed in 42 patients (group 1) and not in 23 pa-
tients (group 2). Of the 142 patients who were treated
without a second TUR, 72 patients received BCG induc-
tion instillations after the initial TUR (group 3) and 70
patients did not (group 4). Patients in group 4 were
older than patients in the other three groups. Patients in
group 1 and group 3, who received BCG therapy, had
more concomitant CIS and higher EAU recurrence risk
score than patients in the two non-BCG treated groups.
The median interval between the initial TUR and the
second TUR was 6.4 weeks (range: from 1.6 to
11.0 weeks, standard deviation 0.53). Of the 65 patients
who underwent a second TUR, residual tumors were de-
tected in 34 patients (52 %). Histopathological findings
were pT0 in 31 cases (48 %), dysplasia in 2 cases (3 %),
Table 1 Patients' characteristics in four groups
Characteristics Group 1 (n = 42) Group 2 (n = 23) Group 3 (n = 72) Group 4 (n = 70)
Follow-up period (months; range) 32.1 (8.9–67.1) 37.1 (8.9–67.1) 32.9 (2.9–64.5) 40.5 (3.7–68.8)
Median age (years; range) 67.8 (39–86) 70.7 (45–84) 72.0 (50–89) 76.6 (43–93)
Gender Male 35 (83.3 %) 19 (83.3 %) 53 (73.6 %) 53 (75.7 %)
Female 7 (16.7 %) 4 (16.7 %) 19 (26.4 %) 17 (24.3 %)
Previous history of UTUC Negative 40 (95.2 %) 23 (100 %) 68 (94.4 %) 64 (91.4 %)
Positive 2 (4.8 %) 0 (0 %) 4 (5.6 %) 6 (85.7 %)
Urine cytology before the initial TUR Negative 9 (21.4 %) 5 (21.7 %) 12 (16.7 %) 26 (37.1 %)
Suspicious positive 23 (54.8 %) 17 (73.9 %) 34 (47.2 %) 31 (44.3 %)
Positive 9 (21.4 %) 0 (0 %) 20 (27.8 %) 9 (12.9 %)
Unknown 1 (2.4 %) 1 (43.5 %) 6 (8.3 %) 4 (5.7 %)
Tumor size <3 cm 29 (69.1 %) 14 (60.9 %) 58 (80.6 %) 13 (18.6 %)
≥3 cm 13 (31.0 %) 9 (39.1 %) 14 (19.4 %) 57 (81.4 %)
Tumor number Single 15 (35.7 %) 14 (60.9 %) 17 (23.6 %) 42 (60 %)
Multiple 27 (64.3 %) 9 (39.1 %) 55 (76.4 %) 28 (40 %)
Concomitant CIS Negative 37 (88.1 %) 23 (100 %) 60 (83.3 %) 68 (97.1 %)
Positive 5 (11.9 %) 0 (0 %) 12 (16.7 %) 2 (2.9 %)
EAU recurrence risk <9 39 (92.9 %) 23 (100 %) 64 (88.9 %) 70 (100 %)
≥10 3 (7.1 %) 0 (0 %) 8 (11.1 %) 0 (0 %)
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atypical gland in 2 cases (3 %), low-grade urotherial car-
cinoma in 5 cases (8 %), high-grade urotherial carcinoma
pTis/a/1 in 25 cases (38 %). There was no upstaged case.
Kaplan–Meier curves of the intravesical RFS of the four
groups are shown in Fig. 2. The 1- and 3-year RFS rates of
the four groups were 83 %, 77 % (group 1), 60 %, 32 %
(group 2), 68 %, 56 % (group 3), and 56 %, 48 % (group 4).
Group 1 had longer RFS than the other three groups
(group 1 vs group 2, 3, 4, p = 0.002, p = 0.045, p < 0.001,
respectively).
Table 2 shows the risk factors for intravesical recur-
rence after a second TUR determined by univariate and
multivariate analyses. BCG induction instillation was the
strongest factor to predict intravesical RFS after the sec-
ond TUR in both univariate and multivariate analyses.
Table 3 shows the characteristics and outcome of the
recurrent cases in the four groups. Recurrent cases
within one year in group 1, 2, 3 and 4 were 7 (17 %), 9
(39 %), 22 (31 %) and 31 (44 %), respectively. With re-
gard to the location of the recurrence in group 1, 2, 3
and 4, recurrence occurred in the same location as the
initial TUR in 3 (14 %), 3 (23 %), 20 (69 %) and 29
(41 %) cases, respectively; on the other hand, recurrence
occurred in a different location in 7 (33 %), 10 (77 %),
12 (41 %) and 22 (31 %) cases, respectively. On the basis
of the RFS in each group and of the location of intravesi-
cal recurrence, patients in group 2, who were treated
with the second TUR without BCG, had more recur-
rence at a different site from the initial tumor; patients
in group 3, who were treated by BCG induction instilla-
tion without a second TUR, had more recurrence at the
same site of the initial tumor. These data indicate that
either BCG alone or a second TUR alone did not pre-
vent intravesical recurrence.
Then, among a total of 31 patients whose pathology of
the second TUR was pT0, we administered BCG induc-
tion instillation in 12 patients who were treated with a
second TUR and in 19 who were not. Only one of the
12 patients (8 %) after BCG induction instillation follow-
ing the second TUR had recurrence, and the location of
the recurrent tumor was the same as the initial tumor.
On the other hand, 11 of 19 patients (58 %) after the
second TUR without BCG had recurrence (Table 4).
Ten of these 11 cases had recurrence at a different site
from the initial tumor; only one had recurrence at the
same site of the initial tumor. These results indicate that
high-grade T1 bladder cancer can recur even after the
tumor has been completely resected, and that BCG in-
duction instillation can prevent ectopic intravesical re-
currence after complete resection.
Discussion
A second TUR plays an important role in both resecting a
residual tumor and detecting staging error. Although re-
cent studies on second TUR referred to both applications
[2–6], we mainly focused on the resection of the residual
tumor in order to clarify the effect of BCG induction in-
stillation following a second TUR. Most studies on second
Fig. 2 Kaplan–Meier curve of the RFS in the four groups (group 1: BCG induction instillations after the second TUR, group 2: a second TUR alone,
group 3: BCG induction instillations alone, group 4: neither a second TUR nor BCG induction instillations). RFS: recurrence-free survival; BCG: Bacillus
Calmette-Guerin; TUR: transurethral resection
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TURs analyzed the efficacy of a second TUR regardless of
BCG induction instillation [2–6, 8]. However, in the
present study, we found that BCG induction instillation
should be performed after the second TUR.
The 1- and 3- year RFS rates after the second TUR
without BCG induction instillations have been described
to be 82 % and 65–68 %, respectively [2, 3]. In the
present study, the 1- and 3- year RFS rates were 68 %
and 56 %, respectively, after BCG induction instillations
following an initial TUR; 60 % and 32 %, respectively,
after the second TUR without BCG; and 84 % and 78 %,
respectively, after the second TUR followed by BCG in-
stillations. Compared with the previous reports, our data
showed lower RFS in the group without BCG following
the second TUR, whereas higher RFS in the group with
BCG following the second TUR.
The recurrence of bladder cancer after the initial TUR
is either represented by the residual tumor due to incom-
plete resection, or by small lesions that have been over-
looked, or by new occurrence caused by implantation of
Table 2 Risk factors for intravesical recurrence after a second TUR
Variables Univariate Multivariate
HR (95 % CI) p-value HR (95 % CI) p-value
Age (≥70) 0.97 (0.85–1.11) 0.68 0.98 (0.79–1.23) 0.87
Gender (female) 1.04 (0.35–3.07) 0.95 1.06 (0.33–3.44) 0.92
Urine cytology before the initial TUR (suspicious positive and positive) 1.52 (0.44–5.22) 0.50 1.77 (0.48–6.54) 0.39
Tumor size (≥3 cm) 1.95 (0.84–4.53) 0.12 2.73 (1.07–7.00) 0.03*
Tumor number (multiple) 0.62 (0.27–1.45) 0.27 0.94 (0.37–2.38) 0.89
Concomitant CIS (existence) 1.23 (0.29–5.25) 0.78 3.21 (0.62–16.67) 0.17
BCG induction instillation (without) 0.28 (0.12–0.67) <0.01** 0.20 (0.07–0.57) <0.01**
*p<0.05, **p<0.01 indicate significant differences
Table 3 Patients' characteristics and outcome of the recurrent cases in the four groups
Characteristics Group 1 (n = 42) Group 2 (n = 23) Group 3 (n = 72) Group 4 (n = 70)
No. of recurrent cases 9 (21 %) 13 (57 %) 29 (40 %) 39 (56 %)
Recurrence within 1 year 7 (17 %) 9 (39 %) 22 (31 %) 31 (44 %)
Median follow-up period
(months; range)
27.8 (11.1–56.5) 20.0 (4.6–62.0) 30.1 (5.6–64.5) 38.2 (3.7–69.5)
Median age (years; range) 74.0 (60–81) 72.9 (45–84) 71.0 (60–84) 78.4 (50–93)
Gender Male 8 (89 %) 10 (77 %) 20 (69 %) 27 (69 %)
Female 1 (11 %) 3 (23 %) 9 (31 %) 12 (31 %)
Tumor size† <3 cm 7 (78 %) 5 (38 %) 24 (83 %) 31 (79 %)
≥3 cm 2 (22 %) 8 (62 %) 5 (17 %) 8 (21 %)
Tumor number† Single 4 (44 %) 8 (62 %) 9 (31 %) 23 (59 %)
Multiple 5 (56 %) 5 (38 %) 20 (69 %) 16 (41 %)
Concomitant CIS† Negative 7 (78 %) 13 (100 %) 24 (83 %) 38 (97 %)
Positive 2 (22 %) 0 (0 %) 5 (17 %) 1 (3 %)
EAU recurrence risk† <9 8 (89 %) 13 (100 %) 25 (86 %) 39 (100 %)
≥10 1 (11 %) 0 (0 %) 4 (14 %) 0 (0 %)
Location of the recurrent tumor†† Same 3 (14 %) 3 (23 %) 20 (69 %) 29 (41 %)
Different 7 (33 %) 10 (77 %) 12 (41 %) 22 (31 %)
Unknown 0 (0 %) 0 (0 %) 1 (3 %) 2 (3 %)
No. of progressed cases who
needed radical cystectomy
3 (7 %) 0 (0 %) 7 (10 %) 4 (6 %)
Outcome NED 9 (100 %) 12 (92 %) 23 (79 %) 31 (79 %)
AWD 0 (0 %) 0 (0 %) 4 (14 %) 4 (10 %)
DOD 0 (0 %) 0 (0 %) 2 (7 %) 2 (5 %)
DOC 0 (0 %) 1 (8 %) 0 (0 %) 2 (5 %)
† characteristics of the initial TUR, †† compared with the initial TUR
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the circulating tumor cells [9]. Although BCG is thought
to be effective against recurrence, BCG therapy against re-
sidual tumors has received little attention in the litera-
tures. Herr HW reported that 67 % of T1 bladder cancers
after BCG therapy without a second TUR failed to re-
spond to BCG, whereas only 24 % of T1 bladder cancers
after BCG induction instillations following second TUR
failed to respond to BCG [4]. He found that BCG had
anti-tumor effect, particularly against CIS, but not against
residual tumors.
According to recent reports, the rates of residual tumors
after an initial TUR were 33–75 % [1, 3, 5, 6]. In our study
we found residual tumors in 54 % of the cases. Our study,
characterized by a relatively high rate of residual tumors
at the initial TUR and early high recurrence rate at the
same sites of the initial TUR, indicates that BCG induc-
tion instillations are not effective against residual tumors.
Comparison of RFS between group 1 and group 3 indi-
cates that a second TUR could prevent recurrence at the
same sites of the initial TUR and that BCG induction in-
stillation was not effective against the residual tumors.
Moreover, among the patients whose pathology of the sec-
ond TUR was pT0, only 8 % who received BCG induction
instillations showed recurrence. On the other hand, in
55 % of the patients who didn’t receive BCG following the
second TUR showed recurrence. Therefore, taking into
account the high recurrence rates of the patients treated
by a second TUR alone with a pT0 pathology, it is recom-
mended to administer BCG therapy following the second
TUR, in order to prevent ectopic intravesical recurrence.
The treatment of all second TURs with BCG induction
instillations might be argued. In our study, we had to
treat all the recurrent cases after second TUR without
BCG with another TUR. Although in this study we
didn’t analyze the effect of BCG following a second TUR
on overall survival, BCG following a second TUR might
have the same effect as BCG following an initial TUR
[10]. In addition, BCG often develops many side effects,
especially in elderly people or patients who take antiplate-
let or anticoagulant agents [11–13]. Recently, preclinical
studies using a novel engineered mycobacterium vaccine
have been conducted to overcome the limitations of
BCG therapy [14]. Therefore, for preventing recur-
rence, in the future it may be feasible to add this
new immunotherapy induction instillations following
a second TUR.
Our study has some limitations. There were no
exact criteria for administering BCG or for undergo-
ing a second TUR. The treatment after the initial
TUR was decided according to the doctors’ choice or
to the policy of each hospital. Moreover, a further
large cohort study is needed.
In conclusion, our study indicates that BCG induction
instillation have limited efficacy against unresected tu-
mors and that BCG induction instillation following a
second TUR clearly prevent intravesical recurrence, even
if there is no residual tumor on the second TUR. Further
prospective randomized investigations are necessary to
understand the role of BCG induction instillation follow-
ing a second TUR.






No. of recurrent cases 1 (8 %) 11 (58 %)
Recurrence within 1 year 1 (8 %) 8 (42 %)
Median follow-up period
(months; range)
17.8 (5.6–33.9) 11.4 (4.1–37.6)
Median age (years; range) 65.5 (39–86) 71.9 (45–84) 0.22
Gender Male 8 (67 %) 15 (79 %) 0.89
Female 4 (33 %) 4 (21 %)
Tumor size <3 cm 8 (67 %) 11 (58 %) 0.30
≥3 cm 4 (33 %) 8 (42 %)
Tumor number Single 6 (50 %) 11 (58 %) 0.63
Multiple 6 (50 %) 8 (42 %)
Concomitant CIS Negative 8 (67 %) 19 (100 %) 0.19
Positive 4 (33 %) 0 (0 %)
EAU recurrence risk <9 11 (92 %) 19 (100 %) 0.07
≥10 1 (8 %) 0 (0 %)
Location of the recurrent tumor† Same 1 (8 %) 1 (5 %)
Different 0 (0 %) 10 (53 %)
† compared with the initial TUR
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Conclusions
BCG induction instillations following a second TUR
clearly prevent intravesical recurrence, even if there is
no residual tumor on the second TUR.
Abbreviation
TUR: Transurethral resection; BCG: Bacillus Calmette-Guerin; RFS: Recurrence-
free survival; CIS: Carcinoma in situ; EAU: European Association of Urologists.
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